Danish Medtech Company Wins Roche Startup Award 2019

Hits:142   Date: 12/20/2019

Founded in 2019 by neuroscientists Brian DellaValle and Casper Hempel, GLX ANALYTIX seeks to detect and monitor brain disease at an earlier stage than before. All this from a simple blood sample.

 

The glycocalyx (GLX) is a seaweed-like glycoprotein meshwork on the luminal surface of blood

vessels. Their idea revolves around a specific signal from the blood vessels, where the glycocalyx (GLX) is released into the blood in specific patterns in response to inflammation and stress. These GLX patterns are extracted and reassembled in a blood sample, like a fingerprint for disease. Since this fingerprint, or GLX Signature, originates from the blood vessel instead of the damaged brain, it can provide earlier information about disease activity than other tests, including an MRI.
 

GLX ANALYTIX is targeting neurodegenerative diseases Multiple Sclerosis, Alzheimer’s and

Parkinson’s Disease with plans to expand into other classes of inflammatory diseases that increase risk for neurodegeneration.

 

"We need better tools for patients, tools that detect whether a drug is working. Companies could also use these tools for developing new medicines and evaluating the effect of existing ones" says CEO Brian DellaValle.
 

 

GLX ANALYTIX just received their first big nod from big pharma as pharmaceutical giant Roche awarded the company its Startup Award at their biennial Future X Healthcare event in Munich the 15th of November.

 

Speaking on the award, Roche’s Global Head of Diagnostics Information Solutions Dr. Tim M. Jaeger says, “At this year’s Future X Healthcare event, we put a spotlight on the patient in the digital era.

 

Consequently, with the FXH 2019 Start-up Award, we were looking for promising start-ups in the field of digital healthcare showing the clear potential to improve the lives of patients.”

“GLX ANALYTIX made it among the more than 150 participants and won the FXH Start-up Award 2019. GLX ANALYTIX won the award with their innovative approach of combining proprietary biomarkers with machine learning for earlier detection and more effective treatment of autoimmune and neurodegenerative diseases. If successful, this approach has a clear potential to improve the lives of patients all over the world.”

 

“We are proud to have received this award as an acknowledgment for our work, our vision, and

our plan, and we look forward to expanding the team and growing the company in 2020 to

transform our research into products” ends Brian DellaValle.

 

About GLX ANALYTIX:

GLX ANALYTIX, as a Biotech startup from Denmark, is focused on bringing personalised medicine to patient’s health care. GLX ANALYTIX is targeting neurodegenerative diseases Multiple Sclerosis, Alzheimer’s and Parkinson’s Disease with plans to expand into other classes of inflammatory diseases that increase risk for neurodegeneration. GLX ANALYTIX recently published in the American Heart Association Journal Stroke about the connection between the GLX and ischemic stroke.

 

About Future X Healthcare 2019

The second edition of Future X Healthcare (www.fxh2019.com) connected approximately 400 innovation drivers in the healthcare sector: global healthcare companies, top researchers, promising start-ups, leading venture capitalists and representatives of politics. The goal is to jointly promote digitization in the healthcare sector for the benefit of patients worldwide. This year, the event initiated by Roche, was under the patronage of the Bavarian State Minister for Digital Affairs Judith Gerlach.

 

GLX Analytix

Dr. Brian DellaValle

Chief Executive Officer & Founder

Copenhagen, Denmark

info@glxanalytix.com   

www.glxanalytix.com